Ricevi le ultime notizie sulle azioni Incyte con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di INCY

Ultime notizie per

INCYTE CORP

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

New,York,City,-,October,5,2017:,The,Brooklyn,Bridge

Large Cap

Mid Cap

News

Small Cap

Markets

Tech

DELL

DLTR

EXPE

INCY

SCHW

TMUS

L&#39;analista di Wall Street identifica occasioni imperdibili in un mercato da record. Ecco le sue strategie per scovare le vere opportunità.

Jim Cramer svela i titoli sottovalutati dell&#39;S&amp;P 500 da non lasciarsi scappare

Meta Platforms Makes AI Moves

Analyst Color

Equities

Government

Market Summary

Futures

Economics

ETFs

AAPL

DECK

Le aziende che &#34;potrebbero soffrire di più&#34; a causa dei dazi di Trump

Incyte Corp

Press Releases

Incyte to Present at Upcoming Investor Conferences

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

RBC Capital

Stifel

B of A Securities

JP Morgan

Wells Fargo

Incyte Pharms

Untitled design (12)

Biotech

ACTU

Vexing challenges await cancer researchers every day — not just in finding new molecules — but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs.



Tumors have their own defense mechanisms, designed to thwart therapeutic intruders, and the immune system is often unable to mount an effective response. 

Actuate Therapeutics Advances A New Era In Oncology With Potential Universal Backbone Therapy

Comments

Incyte Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO